National Institutes of Health, National Cancer Institute: PDQ® Cervical Cancer PreventionArchived 2015-04-08 at the Wayback Machine.. Bethesda, MD: National Cancer Institute. Date last modified 12/17/2015. Accessed 05/20/2015.
Graham, David J; Campen, David; Hui, Rita; et al. (2005). “Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study”. The Lancet365 (9458): 475-481. doi:10.1016/S0140-6736(05)70270-1. PMID15705456.
“Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: A review of the literature”. Gynecological Endocrinology27 (8): 597-604. (2011). doi:10.3109/09513590.2011.558953. PMID21438669.
“Epidemiologic classification of human papillomavirus types associated with cervical cancer”. N. Engl. J. Med.348 (6): 518-27. (2003). doi:10.1056/NEJMoa021641. PMID12571259.
“Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral”. JAMA288 (14): 1749-57. (2002). doi:10.1001/jama.288.14.1749. PMID12365959.
“Management of women who test positive for high-risk types of human papillomavirus: the HART study”. Lancet362 (9399): 1871-6. (2003). doi:10.1016/S0140-6736(03)14955-0. PMID14667741.
“Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia”. J. Natl. Cancer Inst.96 (4): 280-93. (2004). doi:10.1093/jnci/djh037. PMID14970277.
Solomon, C. G.; Solomon, M.; Solomon, D. (2013). “Cervical-Cancer Screening with Human Papillomavirus and Cytologic Cotesting”. New England Journal of Medicine369 (24): 2324-2331. doi:10.1056/NEJMcp1210379. PMID24328466.
Graham, David J; Campen, David; Hui, Rita; et al. (2005). “Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study”. The Lancet365 (9458): 475-481. doi:10.1016/S0140-6736(05)70270-1. PMID15705456.
“Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: A review of the literature”. Gynecological Endocrinology27 (8): 597-604. (2011). doi:10.3109/09513590.2011.558953. PMID21438669.
“Epidemiologic classification of human papillomavirus types associated with cervical cancer”. N. Engl. J. Med.348 (6): 518-27. (2003). doi:10.1056/NEJMoa021641. PMID12571259.
“Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral”. JAMA288 (14): 1749-57. (2002). doi:10.1001/jama.288.14.1749. PMID12365959.
“Management of women who test positive for high-risk types of human papillomavirus: the HART study”. Lancet362 (9399): 1871-6. (2003). doi:10.1016/S0140-6736(03)14955-0. PMID14667741.
“Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia”. J. Natl. Cancer Inst.96 (4): 280-93. (2004). doi:10.1093/jnci/djh037. PMID14970277.
ASCUS-LSIL Traige Study (ALTS) Group (2003). “Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance”. Am. J. Obstet. Gynecol.188 (6): 1383-92. PMID12824967.
Solomon, C. G.; Solomon, M.; Solomon, D. (2013). “Cervical-Cancer Screening with Human Papillomavirus and Cytologic Cotesting”. New England Journal of Medicine369 (24): 2324-2331. doi:10.1056/NEJMcp1210379. PMID24328466.
National Institutes of Health, National Cancer Institute: PDQ® Cervical Cancer PreventionArchived 2015-04-08 at the Wayback Machine.. Bethesda, MD: National Cancer Institute. Date last modified 12/17/2015. Accessed 05/20/2015.